Last reviewed · How we verify

montelukast vs pretreatment with albuterol

University of New Mexico · FDA-approved active Small molecule Quality 2/100

montelukast vs pretreatment with albuterol is a Small molecule drug developed by University of New Mexico. It is currently FDA-approved. Also known as: Singulair is the brand name for montelukast..

At a glance

Generic namemontelukast vs pretreatment with albuterol
Also known asSingulair is the brand name for montelukast.
SponsorUniversity of New Mexico
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about montelukast vs pretreatment with albuterol

What is montelukast vs pretreatment with albuterol?

montelukast vs pretreatment with albuterol is a Small molecule drug developed by University of New Mexico.

Who makes montelukast vs pretreatment with albuterol?

montelukast vs pretreatment with albuterol is developed and marketed by University of New Mexico (see full University of New Mexico pipeline at /company/university-of-new-mexico).

Is montelukast vs pretreatment with albuterol also known as anything else?

montelukast vs pretreatment with albuterol is also known as Singulair is the brand name for montelukast..

What development phase is montelukast vs pretreatment with albuterol in?

montelukast vs pretreatment with albuterol is FDA-approved (marketed).

Related